id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S15197 R62331 |
Cohen (Lamotrigine) (Mixed indications), 2023 | Clubfoot | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Partial overlapping | 1.04 [0.69;1.56] | -/8,339 -/4,866,362 | - | 8,339 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10035 R36169 |
Blotière (Lamotrigine) (Mixed indications), 2019 | Talipes equinovarus | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 0.70 [0.10;2.70] | 2/2,997 1,677/1,875,733 | 1,679 | 2,997 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8971 R30406 |
Dolk (Lamotrigine) (Mixed indications), 2016 | All clubfoot | 1st trimester | case control | unexposed (general population or NOS) | Adjustment: Yes | 1.60 [0.81;3.15] | 9/ -/- | - | 0 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8908 R30106 |
Källén (Lamotrigine) (Indications NOS), 2013 | Pes equinovarus | early pregnancy | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: No Partial overlapping | 0.68 [0.10;4.86] C | 1/1,084 2,127/1,575,847 | 2,128 | 1,084 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 1.12 [0.80;1.57] | 3,807 | 12,420 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Lamotrigine) (Mixed indications; 2: Lamotrigine) (Mixed indications; 3: Lamotrigine) (Mixed indications; 4: Lamotrigine) (Indications NOS;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded